ArticleFrontiers in oncology2022

Rapid response to monotherapy with MEK inhibitor trametinib for a lung adenocarcinoma patient harboring primary

Yang Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.